AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences of Idiopathic Intracranial Hypertension to Boost Growth | Technavio

February 6, 2020 GMT
Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences of Idiopathic Intracranial Hypertension to Boost Growth | Technavio
Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences of Idiopathic Intracranial Hypertension to Boost Growth | Technavio

LONDON--(BUSINESS WIRE)--Feb 6, 2020--

Technavio has been monitoring the idiopathic intracranial hypertension therapeutics market and it is poised to grow by USD 15.34 mn during 2019-2023, progressing at a CAGR of 3% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200206005429/en/

Technavio has announced its latest market research report titled global idiopathic intracranial hypertension therapeutics Market 2019-2023 (Graphic: Business Wire)

Rising incidences of idiopathic intracranial hypertension has been instrumental in driving the growth of the market. However, a limited patient pool might hamper market growth. Request a free sample report

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Segmentation

Idiopathic Intracranial Hypertension Therapeutics Market is segmented as below:

Product

Geographic segmentation

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR32189

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our idiopathic intracranial hypertension therapeutics market report covers the following areas:

This study identifies increasing number of awareness campaigns as one of the prime reasons driving the idiopathic intracranial hypertension therapeutics market growth during the next few years.

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the idiopathic intracranial hypertension therapeutics market, including some of the vendors such as AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd. Backed with competitive intelligence and benchmarking, our research reports on the idiopathic intracranial hypertension therapeutics market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio’s SUBSCRIPTION platform

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Key Highlights

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200206005429/en/

CONTACT: Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email:media@technavio.com

Website:www.technavio.com/

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH MENTAL HEALTH

SOURCE: Technavio Research

Copyright Business Wire 2020.

PUB: 02/06/2020 06:30 AM/DISC: 02/06/2020 06:30 AM

http://www.businesswire.com/news/home/20200206005429/en